Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Richmond, Victoria, Australia Clinical Trials

A listing of Richmond, Victoria, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (761) clinical trials

Safety and Efficacy Study of RP4010 in Patients With Relapsed or Refractory Lymphomas

Safety: Treatment-Emergent Adverse Events (AE); Treatment related AE, Serious Adverse Events (SAE) and Clinical significant AE; Dose Limiting Toxicities (DLT). Pharmacokinetics (PK): Peak Plasma Concentration (Cmax), Area under the plasma concentration versus time curve (AUC), Time of Maximum Concentration Observed (Tmax). Efficacy: Overall Response Rate (ORR), Progression Free Survival (PFS); ...

Phase

0.0 miles

Learn More »

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.

Phase

0.0 miles

Learn More »

Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC)

The introduction of direct-acting antiviral (DAA) therapies has meant the elimination of hepatitis C (HCV) as a public health issue in Australia is a very real possibility. The challenge that remains is to ensure that all people living with HCV can access testing to become aware of their status, and ...

Phase N/A

0.0 miles

Learn More »

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Phase

0.0 miles

Learn More »

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Primary Objective: To evaluate the safety and tolerability of subcutaneous (SC) blinatumomab dose administrations Secondary Objectives: To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations To estimate the maximum tolerated dose (MTD) tested for blinatumomab administered subcutaneously To determine the incidence of anti-blinatumomab antibody formation following SC administration ...

Phase

0.0 miles

Learn More »

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Subjects With B-cell Malignancies

This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in subjects with B-cell lymphoid malignancies.

Phase

0.0 miles

Learn More »

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

Lung cancer is the leading cause of cancer-related mortality worldwide. A report published by the WHO in February 2014, estimated there were 1.83 million new cases and 1.59 million deaths worldwide in 2012. The American Lung Association reports 399,431 Americans living with lung cancer, with an estimated 221,200 new cases ...

Phase

0.0 miles

Learn More »

A Dose-escalation Study of ARX788 IV Administered in Subjects With Advanced Cancers With HER2 Expression

This is a 2-part, Phase 1 FIH study with Phase 1a designed to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) in subjects with metastatic cancers with a human epidermal growth factor receptor 2 (HER2) test result that is in situ hybridization (ISH) positive (+) or immunohistochemistry (IHC) ...

Phase

0.0 miles

Learn More »

The DIAMOND for the Treatment of Type 2 Diabetes

Study to evaluate the efficacy of gastric stimulation (GCM) using the DIAMOND System in the improvement of glycemic control measured by changes in HbA1c. Relationship between blood TG level and the GCM efficacy will be evaluated.

Phase N/A

0.0 miles

Learn More »

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Phase

0.0 miles

Learn More »